NCT03097939View on ClinicalTrials.gov

Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

113

Participants

Timeline

Start Date

March 31, 2017

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Nasopharyngeal Carcinoma
Interventions
DRUG

Ipilimumab

1 mg/kg of IV Ipilimumab is admistered over 90 minutes every 6 weeks

DRUG

Nivolumab

3 mg/kg of IV Nivolumab is administered over 30 minutes every 2 weeks

Trial Locations (1)

169610

RECRUITING

National Cancer Center Singapore, Singapore

All Listed Sponsors
collaborator

National University of Singapore

OTHER

collaborator

National Taiwan University Hospital

OTHER

lead

National Cancer Centre, Singapore

OTHER